47 results about "Taxane" patented technology

The application discloses a micelle containing a taxane drug, a preparation method and application thereof. The application provides a micelle containing substance A, which comprises the following components in parts by weight: 1 part of substance A and 5-25 parts of polyethylene glycol derivatized phospholipid; the substance A is docetaxel and / or cabazitaxel; and the polyethylene glycol derivatized phospholipid comprises a polyethylene glycol part and a phospholipid part, wherein the phospholipid part is di(C 12 ‑C 24 phosphatidylethanolamine. The micelle containing the taxane drug can contain a therapeutically effective amount of the taxane drug, the drug loading capacity is as high as 6.25%-9.09%, the stability is good, and the problems in clinical application can be effectively solved.

To provide a pharmaceutical composition for treating a subject affected with cancer.SOLUTION: A pharmaceutical composition containing an effective dose of FABP5 inhibitor to be used in combination with anti-cancer therapy or additionally used to anti-cancer therapy in treatment of a subject affected with cancer, where the FABP5 inhibitor has the following structure or an enantiomer or a racemate thereof, or a pharmaceutically acceptable salt thereof.SELECTED DRAWING: None

A taxane composition and use thereof. The taxane composition is a taxane aqueous composition comprising a taxane. The taxane aqueous composition is used for treating an individual with bladder cancer by means of intravesical instillation, and has at least one of the following characteristics: (1) at least about 5% of the taxane is free taxane; and (2) the concentration of the free taxane is about 0.01 mg / ml to about 0.8 mg / ml. Alternatively, the taxane aqueous composition is used for treating a bladder cancer patient by means of intravesical instillation; after the taxane aqueous composition is administrated to the bladder cancer patient, the taxane in the plasma of the bladder cancer patient has at least one of the following characteristics: (1) the concentration of the taxane in the plasma of the bladder cancer patient is at least about 0.02 ng / ml; and (2) the AUC of the taxane in the plasma of the bladder cancer patient is at least about 0.02 h*ng / mL.

To provide, considering potential clinical oral dosing regimens for taxanes, improved tablet formulations of taxanes having higher dosage strength and higher bioavailability.SOLUTION: The invention relates to high-strength, high-bioavailability, ready-to-administer oral compositions of taxanes to be manufactured by readily scalable methods. The ready-to-administer oral composition can comprise a solid dispersion of taxanes and a hypromellose acetate succinate (HPMCAS) carrier, which is compressed into a tablet form with high taxane loading.SELECTED DRAWING: Figure 9

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More in particular it relates to a method for the treatment of a cancer in a patient comprising orally administering an effective dose of docetaxel, whereby side effects are controlled by preventing peak plasma levels of docetaxel that induce said side effects, whilst maintaining an effective plasma level of docetaxel to eradicate tumor cells.

A taxane supramolecular nanocomposite. The supramolecular nanocomposite comprises a taxane active substance, including but not limited to paclitaxel, docetaxel, and cabazitaxel, as well as a self-assembling carrier, a high molecular polymer, and a dissolution promoter. The dissolution promoter may comprise one or more of alcohols, polybasic organic acids, and amino acids. Also disclosed are a preparation method and use of the supramolecular nanocomposite. The supramolecular nanocomposite is suitable for oral administration and topical application, providing effects such as increased local drug exposure concentration and efficacy, reduced systemic side effects, etc.

The present disclosure is directed to linker-payload compounds, and pharmaceutically acceptable salts, solvates, or stereoisomer thereof, comprising a structure of formula (I) which are useful as a component of antibody-drug conjugates. The disclosure also provides antibody-drug conjugates comprising the linker-payload compounds, compositions thereof, and methods of using the antibody-drug conjugates for the treatment of cancer.

Provided is a pharmaceutically acceptable formulation comprising a taxane and an acid-activated 2-hydroxypropyl-β-cyclodextrin (CD). Also provided is a method of treating a patient with a taxane. The method comprises infusing the above formulation into the patient. Additionally provided is a method of preparing the above formulation. Further provided is an infusion bag comprising the above formulation.

The invention discloses an application of docetaxel in preparation of drugs for resisting toxoplasmosis, and belongs to the technical field of medicines. Through a series of experimental studies, it is found that docetaxel can significantly delay the onset time of mice infected with toxoplasma gondii virulent strains and effectively reduce the death rate of mice infected with toxoplasma gondii attenuated strains. Docetaxel shows a relatively strong inhibition effect in the aspect of treating related diseases caused by a virulent strain or a low virulent strain of toxoplasma gondii, and can effectively slow down the infection process and prolong the life cycle of a host. In combination with in-vitro cell experiment and in-vivo animal experiment results, the taxane drug has a good treatment prospect, can be used as a development basis of a novel toxoplasmosis-resistant drug, and promotes the realization of a novel treatment scheme.

Peptides that selectively bind ENAH (MENA) are described. The peptides are useful for treating certain cancers, such as triple negative breast cancer and for reducing resistance to taxane therapy.

The present disclosure provides methods for treating or preventing cancer comprising administering antigen binding molecules and taxane and / or nucleoside analogs that bind HER3. Also provided are methods for treating or preventing cancer comprising administering an antigen-binding molecule that binds HER3 and an antigen-binding molecule that binds EGFR. Also provided are pharmaceutical compositions and pharmaceutical combinations comprising such medicaments, as well as therapeutic and prophylactic methods of using the pharmaceutical compositions / pharmaceutical combinations.

The present invention concerns antibody-conjugate having general structure (2):wherein AB is an antibody capable of targeting Trop-2-expressing tumours and D is selected from the group consisting of taxanes, anthracyclines, camptothecins, epothilones, mytomycins, combretastatins, vinca alkaloids, maytansinoids, enediynes such as calicheamicins, duocarmycins, tubulysins, amatoxins, bleomycins, dolastatins and auristatins, pyrrolobenzodiazepine dimers, indolinobenzodiazepine dimers, radioisotopes, therapeutic proteins and peptides (or fragments thereof), kinase inhibitors, MEK inhibitors, KSP inhibitors, and analogues or prodrugs thereof. These antibody-conjugates exhibit an improved therapeutic index. The invention further concerns a process for preparing the antibody-conjugate according to the invention, a method for targeting Trop-2-expressing cells, medical uses of the antibody-conjugates according to the invention.

The invention belongs to the technical field of tumor resistance, and particularly relates to a taxane composition and application thereof. The taxane composition is an aqueous taxane composition comprising taxane for use in the treatment of a subject with bladder cancer by bladder perfusion, having at least one of the following features: (1) wherein at least about 5% of the taxane is free taxane; (2) wherein the concentration of free taxane is from about 0.01 mg / ml to about 0.8 mg / ml. Or, the aqueous taxane composition is used for treating a bladder cancer patient through bladder perfusion, and after the aqueous taxane composition is applied to the bladder cancer patient, the taxane in the plasma of the bladder cancer patient has at least one of the following characteristics: (1) the concentration of the taxane in the plasma of the bladder cancer patient is at least about 0.02 ng / ml; (2) the AUC of the taxane in the plasma of the bladder cancer patient is at least about 0.02 h * ng / mL.

IT-139, sodium trans-[tetrachlorobis(1H-indazole)ruthenate(III)], is an intravenously administered small molecule compound. In preclinical anti-tumor and mechanism of action studies, IT-139 showed activity against a broad range of tumor types, including those which are resistant to standard anti-cancer agents (e.g., platinums, vinca alkaloids, taxanes, anthracyclines). This activity is believed to arise from IT-139's novel mechanism of action that targets the GRP78 pathway. It was found that up-regulation of GRP78 is a key cancer cell survival pathway. Downregulation of GRP78 using IT-139 removes this resistance pathway allowing for chemotherapy and immuno-oncology agents to be more effective in treating cancer.

The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.

Use of a LAG-3 protein or derivative thereof for the treatment of a cancer in a subject is described. In certain aspects, the subject has one or more of: a low monocyte count; a Luminal B breast cancer; an age of less than about 85 years; has been previously treated with a CDK4 / 6 inhibitor; has not previously undergone treatment with a taxane chemotherapy; has an elevated neutrophil to lymphocyte ratio; been diagnosed less than about 5 years ago. In another aspect, the LAG-3 protein or derivative is administered to the subject at a dosage of a molar equivalent of >30 mg to <120 mg of LAG-3 derivative LAG-3Ig fusion protein IMP321. In a further aspect, the LAG-3 protein, or derivative, is administered to the subject on the same day as a chemotherapy agent. In another aspect, the LAG-3 protein, or derivative, is administered to the subject one or more times in the absence of a chemotherapy agent, after one or more dosages of the LAG-3 protein, or derivative, have been administered to the subject before, with, or after one or more dosages of the chemotherapy agent. In a further aspect, the subject is a hormone receptor-positive HER2-neg / low (HR+ / HER2-neg / low) metastatic breast cancer patient, or a metastatic triple negative breast cancer (TNBC) patient.

The present disclosure relates to combination therapies for the treatment of cancer. In particular, the disclosure relates to combination therapy with a CXCR4 inhibitor and a taxane for the treatment of cancer. In some aspects, the disclosure relates to combination therapy with a CXCR4 inhibitor and a taxane for the treatment of tumors in the bone of a subject.

The present invention relates generally to methods of treating HER2-positive locally advanced or previously untreated metastatic breast cancer, and particularly provides methods of treating HER2-positive, locally advanced or previously untreated metastatic breast cancer with an anti-HER2-maytansine conjugate (e.g., trastuzumab-eimetanin) that has received prior treatment with a taxane, a method of treating a patient with locally advanced or previously untreated metastatic breast cancer.

Disclosed are a method for biological total synthesis of paclitaxel key precursor substance baccatin III, a biological material and use thereof. The bioenzyme composition used in the method comprises a taxane 9α-hydroxylase (T9αH) and a taxane C4-C20 oxetanase (TOT). According to the disclosure, a core component of a baccatin III biosynthetic pathway is identified, a baccatin III artificial synthesis route is constructed, thereby paving the way for efficiently developing a green low-carbon production pathway of taxane products (such as paclitaxel) through synthetic biology.

The present invention relates to a method for treating human breast cancers using combination therapy that includes therapeutically effective amounts of an iNOS inhibitor, a PI3K-ATK pathway inhibitor, and ataxane.

The present invention relates to nanoparticles containing taxane and albumin and having improved stability in maintaining particle size distribution, and a method for producing the same. The method for producing nanoparticles of the present invention is useful as an improved method for producing nanoparticles since the average size of the nanoparticles is uniform over time and the structural stability and particle size distribution are excellent compared to nanoparticles containing taxane and albumin produced by conventional processes.

The present application relates to the technical field of synthetic biology, in particular to a novel taxane acetyl hydrolase, nucleic acid molecule, biological material and application thereof. The acetyl hydrolase comprises at least one of the following sequences: the amino acid sequence of the enzyme shown in SEQ ID NO. 1, SEQ ID NO. 9, SEQ ID NO. 16, SEQ ID NO. 19, SEQ ID NO. 21, SEQ ID NO. 24 or a protein with the same function obtained by substitution and / or deletion and / or addition. The above-mentioned biological enzyme has stronger site selectivity and more controllable product spectrum, has clear regional selectivity for taxane acetyl hydrolysis, can reduce excessive hydrolysis and by-products caused by chemical hydrolysis or non-specific esterase, and has important value for green manufacturing application of taxane.

The present invention relates to a novel chemical compound for use in the treatment of cancer, to compositions containing said compound, methods of manufacture and combinations with other therapeutic agents.

The invention relates to a bispecific antibody construct, a taxane, and / or an immune checkpoint inhibitor for use in a method of treating a tumor in a subject, wherein the bispecific antibody construct comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR, wherein the method comprises administering to the subject the bispecific antibody construct, the taxane, and the immune checkpoint inhibitor. The invention further relates to a composition comprising a taxane and a bispecific antibody construct that comprises at least one first binding domain capable of specifically binding CD16A and at least one second binding domain capable of specifically binding EGFR.

The invention relates to the field of medicines, and particularly discloses a paclitaxel derivative shown in a formula (I) as well as a preparation method and application of the paclitaxel derivative. A baccatin diazo compound, imine and alcohol are used as raw materials, transition metal rhodium is used as a catalyst, and the paclitaxel derivative is obtained after a period of time of reaction at a certain temperature. According to the invention, efficient modular synthesis of the paclitaxel derivative can be realized. Benefited from the rapid synthesis method, large-scale anticancer activity screening is carried out on the paclitaxel derivatives, the antitumor activity of the paclitaxel derivatives in a cell level and a mouse model is superior to that of paclitaxel, and part of the paclitaxel derivatives show better anticancer activity in a paclitaxel drug-resistant cell model. The discovery of novel taxane medicines is facilitated.

Described herein are methods of treating cancer m a subject by administering a therapeutically effective amount of an AP2 associated kinase 1 (AAK1 ) inhibitor and a therapeutically effective amount of a taxane or a vinca alkaloid. -Also disclosed herein are methods of enhancing the responsiveness of a cancer cell to a taxane or a vinca alkaloid, and methods of increasing the efficacy of a taxane or a vinca alkaloid in a subject with cancer by administering a therapeutically effective amount of an AAK1 inhibitor and a therapeutically effective amount of a taxane or a vinca alkaloid. Hie methods can be useful in subjects with cancer that are resistant to the taxane or a vinca alkaloid prior to the administration of the AAK1 inhibitor.

The present disclosure relates to a method for treating prostate-specific membrane antigen (PSMA)-positive advanced metastatic castration-resistant prostate cancer (mCRPC) by administering a therapeutically effective amount of a PSMA-conjugated radioligand therapy (RLT) agent, preferably [177Lu]Lu-PSMA-617 (lutetium (177Lu) bipibotide tetraxetane), to taxane-naive patients who have progressed after receiving a second-generation ARPI.

The application discloses a prediction model training method for predicting the relative curative effects of EC and T in NAC, and the method comprises the following steps: acquiring MRI image data and clinical pathological data of a subject to construct a data set, and constructing an imageomics model based on DCE and ADC sequences through image segmentation, feature extraction, qualitative relative curative effect feature, model construction and verification, and a mixed model combined with clinical pathological factors is used to predict the relative curative effects of EC and T treatment. The application can effectively predict the relative curative effects of EC (epirubicin plus cyclophosphamide) and T (taxane drugs) treatment schemes in the middle stage of NAC, so as to timely adjust the treatment scheme and improve the treatment effect.